These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 912593

  • 21. [Long-term treatment of renalosteodystrophy with 1 alpha-hydroxycholecalciferol].
    Marco Franco JE, Alarcón Zurita A, Pizá Buñola C, Morey Molina A, Bestard Palmer J, Mairata Bosch S, Dalmau Diana M.
    Rev Clin Esp; 1982 Jan 15; 164(1):33-5. PubMed ID: 7071401
    [No Abstract] [Full Text] [Related]

  • 22. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG, Russell RG, Ledingham JG, Smith R, Oliver DO, Walton RJ, Small DG, Preston C, Warner GT.
    Lancet; 1974 Mar 09; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. 1alpha-hydroxycholecalciferol. Long-term treatment of patients with uraemic osteodystrophy.
    Nielsen SP, Binderup E, Godtfredsen WO, Jensen H, Ladefoged J.
    Nephron; 1976 Mar 09; 16(5):359-70. PubMed ID: 1264309
    [Abstract] [Full Text] [Related]

  • 25. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
    Baker LR, Muir JW, Cattell WR, Tucker KA, Sharman VL, Goodwin FJ, Marsh FP, Hately W, Morgan AG, de Saintonge DM.
    Contrib Nephrol; 1980 Mar 09; 18():147-51. PubMed ID: 7353373
    [Abstract] [Full Text] [Related]

  • 26. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
    Postlethwaite RJ, Houston IB.
    Clin Endocrinol (Oxf); 1977 Dec 09; 7 Suppl():117s-124s. PubMed ID: 304772
    [Abstract] [Full Text] [Related]

  • 27. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
    Coburn JW, Brickman AS.
    Adv Exp Med Biol; 1978 Dec 09; 103():473-86. PubMed ID: 362852
    [No Abstract] [Full Text] [Related]

  • 28. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
    Nielsen HE, Melsen F, Christensen MS, Hansen HE, Rodbro P, Johannsen A.
    Clin Nephrol; 1977 Oct 09; 8(4):429-34. PubMed ID: 923161
    [No Abstract] [Full Text] [Related]

  • 29. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL, Brownjohn AM, Goodwin FJ, Hately W, Manning RM, O'Riordan JH, Papapoulos SE, Marsh FP.
    Q J Med; 1982 Oct 09; 51(203):271-8. PubMed ID: 7146311
    [Abstract] [Full Text] [Related]

  • 30. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM, Ellis HA, Simpson W, Cook D, Kerr DN.
    Clin Endocrinol (Oxf); 1977 Dec 09; 7 Suppl():109s-116s. PubMed ID: 606409
    [Abstract] [Full Text] [Related]

  • 31. Calcitriol in dialysis patients.
    Maxwell DR, Benjamin DM, Donahay SL, Allen MK, Hamburger RJ, Luft FC.
    Clin Pharmacol Ther; 1978 May 09; 23(5):515-9. PubMed ID: 205382
    [Abstract] [Full Text] [Related]

  • 32. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL, Marie A, Kuntz D, Marie P, Gueris J, Smadja A, Fournier A, Quichaud J.
    Rev Rhum Mal Osteoartic; 1981 May 09; 48(7-9):535-41. PubMed ID: 7291931
    [Abstract] [Full Text] [Related]

  • 33. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM, Davin JC, Lambrechts L, Heynen G.
    Ann Endocrinol (Paris); 1979 May 09; 40(2):161-2. PubMed ID: 475307
    [Abstract] [Full Text] [Related]

  • 34. Evidence that different vitamin D sterols have qualitatively different effects in man.
    Rasmussen H, Bordier P.
    Contrib Nephrol; 1980 May 09; 18():184-91. PubMed ID: 7353375
    [No Abstract] [Full Text] [Related]

  • 35. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G, Taccone Gallucci M, Bonucci E, Ballanti P, Bianchi AR, Bianchini G, Matteucci MC, Mazzaferro S, Picca S, Taggi F, Cinotti GA, Casciani CU.
    Miner Electrolyte Metab; 1983 May 09; 9(1):19-27. PubMed ID: 6687749
    [No Abstract] [Full Text] [Related]

  • 36. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y, Olmer M, Grandvuillemin M, Lachaize AM.
    Sem Hop; 1983 May 09; 57(9-10):445-9. PubMed ID: 6261385
    [Abstract] [Full Text] [Related]

  • 37. The investigation and treatment of renal osteodystrophy.
    Catto GR, MacLeod M, Pelc B, Kodicek E.
    Proc Eur Dial Transplant Assoc; 1975 May 09; 11():473-80. PubMed ID: 1197272
    [Abstract] [Full Text] [Related]

  • 38. Comparison of whole body and regional assessments of calcium balance in renal osteodystrophy in the response to 1 alpha-hydroxy vitamin D3.
    Naik RB, Robertson PW, Robinson BH, Dabek JT, James HM, Kanis JA.
    Proc Eur Dial Transplant Assoc; 1977 May 09; 14():425-32. PubMed ID: 600960
    [Abstract] [Full Text] [Related]

  • 39. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.
    Madsen S, Olgaard K.
    Acta Med Scand; 1976 May 09; 200(1-2):1-5. PubMed ID: 961464
    [Abstract] [Full Text] [Related]

  • 40. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM, Kerr DN, Ellis HA, Peart KM, O'Riordan JL, DeLuca HF.
    Clin Nephrol; 1976 Apr 09; 3(2):189-96. PubMed ID: 819195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.